Biologica, Inc.

Biologica, Inc. is a health supplement company based in the US, dedicated to developing innovative products specifically for women across various hormonal stages of life. Founded in 2024 and headquartered in San Francisco, US, Biologica, Inc. focuses on health supplements tailored for women.

In December 2025, Biologica, Inc. raised USD 7 million in seed funding led by Addition, with participation from Hawktail, Greycroft, True Beauty Ventures and Good Friends. Individual investors also participated in the round. Biologica specializes in health supplements specifically formulated for women at different hormonal stages: reproductive years, perimenopause, and postmenopause.

The company offers three core products—Primary Essentials, Midlife Essentials, and Postmenopause Essentials—each a 4-in-1 beverage containing essential vitamins, minerals, probiotics, and botanicals designed to address the unique health concerns associated with each life stage. With a focus on clinical integrity, these products are backed by research and formulated to enhance mood balance, energy levels, metabolism, digestive support, and restful sleep. Biologica's products are primarily targeted toward women aged 18 and above, with a particular focus on those experiencing hormonal changes. The company markets its offerings in North America and select international markets, aiming to meet the needs of women seeking effective, enjoyable health solutions.

Biologica operates a direct-to-consumer business model, utilizing subscription services and one-time purchases as its primary transaction structures. Customers can choose to buy individual products or sign up for regular deliveries, often at a discounted rate, which enhances customer retention and revenue predictability. Pricing for Biologica's flagship offerings, such as the Primary Essentials and Midlife Essentials, is set at USD 70, with subscription prices reflecting a 16% discount. This structure encourages ongoing consumer engagement and loyalty.

Revenue streams are further supported by the appeal of their clinically-backed formulations, which attract a growing customer base of women focused on health and wellness. The company’s commitment to quality and efficacy is underscored by its third-party testing and adherence to regulatory standards, positioning it as a reliable choice in the health supplement market. In December 2025, Biologica, Inc. raised USD 7 million in SEED funding from unspecified investors.

The company plans to utilize this funding to launch and scale a nutritional supplement brand focused on hormonal health. They aim to introduce new products that cater to specific hormonal health needs and expand their market presence into additional international regions by the end of 2026.